CONCLUSIONS	Pioglitazone 30 mg QD did not affect the pharmacokinetics of topiramate at steady state , while coadministration of topiramate 96 mg BID with pioglitazone decreased steady-state systemic exposure to pioglitazone , M-III , and M-IV .\